Nathaniel Brown

9.4k total citations · 3 hit papers
87 papers, 7.0k citations indexed

About

Nathaniel Brown is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Nathaniel Brown has authored 87 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Epidemiology, 55 papers in Hepatology and 32 papers in Infectious Diseases. Recurrent topics in Nathaniel Brown's work include Hepatitis C virus research (53 papers), Hepatitis B Virus Studies (49 papers) and HIV/AIDS drug development and treatment (27 papers). Nathaniel Brown is often cited by papers focused on Hepatitis C virus research (53 papers), Hepatitis B Virus Studies (49 papers) and HIV/AIDS drug development and treatment (27 papers). Nathaniel Brown collaborates with scholars based in United States, China and Canada. Nathaniel Brown's co-authors include Lynn D. Condreay, Eugene R. Schiff, Jules L. Dienstag, Ching‐Lung Lai, Mary Woessner, Zachary Goodman, Teresa L. Wright, Robert G. Gish, George Chao and Kathie‐Anne Walters and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Nathaniel Brown

85 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States

1999 976 citations Jules L. Dienstag, Eugene R. Schiff et al. New England Journal of Medicine profile →
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine

1998 675 citations Nathaniel Brown, Lynn D. Condreay et al. Hepatology profile →
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B

2007 578 citations Ching‐Lung Lai, Edward Gane et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathaniel Brown United States	30	6.0k	5.7k	1.6k	390	290	87	7.0k
Gunnar Norkrans Sweden	44	4.4k 0.7×	4.2k 0.7×	1.1k 0.7×	140 0.4×	73 0.3×	195	6.2k
Natalie Bzowej United States	25	6.5k 1.1×	6.1k 1.1×	689 0.4×	240 0.6×	49 0.2×	59	7.3k
Julian Schulze zur Wiesch Germany	39	2.2k 0.4×	2.3k 0.4×	1.3k 0.8×	341 0.9×	447 1.5×	198	5.4k
Jian Sun China	28	2.0k 0.3×	1.7k 0.3×	501 0.3×	145 0.4×	130 0.4×	122	2.9k
Martin Lagging Sweden	32	2.8k 0.5×	3.2k 0.6×	528 0.3×	235 0.6×	22 0.1×	116	4.1k
Jörg Timm Germany	35	1.9k 0.3×	2.5k 0.4×	1.4k 0.9×	213 0.5×	89 0.3×	145	4.7k
J. Rasenack Germany	32	3.6k 0.6×	3.8k 0.7×	400 0.2×	241 0.6×	17 0.1×	71	4.9k
Yasuyuki Arakawa Japan	29	2.5k 0.4×	2.9k 0.5×	417 0.3×	296 0.8×	21 0.1×	121	4.2k
Jean‐Pierre Zarski France	36	4.1k 0.7×	4.1k 0.7×	505 0.3×	140 0.4×	18 0.1×	144	5.3k
Thomas von Hahn Germany	32	2.0k 0.3×	2.2k 0.4×	717 0.4×	165 0.4×	39 0.1×	105	4.5k

Countries citing papers authored by Nathaniel Brown

Since Specialization

Citations

This map shows the geographic impact of Nathaniel Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathaniel Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathaniel Brown more than expected).

Fields of papers citing papers by Nathaniel Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathaniel Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathaniel Brown. The network helps show where Nathaniel Brown may publish in the future.

Co-authorship network of co-authors of Nathaniel Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Nathaniel Brown. A scholar is included among the top collaborators of Nathaniel Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathaniel Brown. Nathaniel Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

James, Lois, et al.. (2020). Sleep health and predicted cognitive effectiveness of nurses working 12-hour shifts: an observational study. International Journal of Nursing Studies. 112. 103667–103667. 52 indexed citations

Yuen, Man‐Fung, Edward Gane, Dong Joon Kim, et al.. (2019). Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology. 156(5). 1392–1403.e7. 117 indexed citations

Fontana, Robert J., Mark Avigan, Harry L.A. Janssen, et al.. (2019). Liver safety assessment in clinical trials of new agents for chronic hepatitis B. Journal of Viral Hepatitis. 27(2). 96–109. 11 indexed citations

Lalezari, Jacob, Pamela Vig, Jerry O. Stern, et al.. (2014). O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN. Journal of Hepatology. 60(1). S27–S27. 3 indexed citations

Huang, Qi, Ningwu Huang, Jacob Lalezari, et al.. (2013). 1192 VAST MAJORITY OF DETECTED NS5A RESISTANT VARIANTS ARE NOT AMPLIFIED IN HCV PATIENTS DURING 3-DAY MONOTHERAPY WITH THE OPTIMIZED NS5A INHIBITOR PPI-668. Journal of Hepatology. 58. S485–S485. 4 indexed citations

Huang, Chaorui, Paul J. Mattis, Kenneth Perrine, et al.. (2008). Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 70(16_part_2). 1470–1477. 191 indexed citations

Lai, Ching‐Lung, et al.. (2007). [493] ADEFOVIR SALVAGE THERAPY FOR VIROLOGIC BREAKTHROUGH IN TELBIVUDINE-TREATED PATIENTS FROM THE GLOBE STUDY. Journal of Hepatology. 46. S187–S188. 8 indexed citations

Hu, Pei, Ji Jiang, Hongyun Wang, et al.. (2006). Single‐Dose and Multiple‐Dose Pharmacokinetics and Safety of Telbivudine After Oral Administration in Healthy Chinese Subjects. The Journal of Clinical Pharmacology. 46(9). 999–1007. 17 indexed citations

Lai, Ching‐Lung, Jules L. Dienstag, Eugene R. Schiff, et al.. (2003). Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B. Clinical Infectious Diseases. 36(6). 687–696. 497 indexed citations

10.

Schiff, Eugene R., Jules L. Dienstag, Selim Karayalçın, et al.. (2003). Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. Journal of Hepatology. 38(6). 818–826. 95 indexed citations

11.

Perrillo, Robert P., Ching‐Lung Lai, Yun‐Fan Liaw, et al.. (2002). Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 36(1). 186–194. 238 indexed citations

12.

Metcalf, Marilyn, et al.. (1999). Health care costs associated with chronic hepatitis B. American Journal of Health-System Pharmacy. 56(3). 232–236. 15 indexed citations

13.

Gauthier, Josée, Eric Bourne, Michael W. Lutz, et al.. (1999). Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with Lamivudine. The Journal of Infectious Diseases. 180(6). 1757–1762. 100 indexed citations

14.

Dienstag, Jules L., Eugene R. Schiff, Teresa L. Wright, et al.. (1999). Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. New England Journal of Medicine. 341(17). 1256–1263. 976 indexed citations breakdown →

15.

Atkins, Mark, Nathaniel Brown, Mary Woessner, et al.. (1998). Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients.. UCL Discovery (University College London). 13 indexed citations

16.

Rizzetto, Mario, P Opolon, Robert Goldin, et al.. (1998). Sustained histologic response is common in the absence of virologic response to interferon (IFN) therapy for chronic hepatitis C (HCV). Gastroenterology. 114. A1291–A1291. 3 indexed citations

17.

Dienstag, Jules L., Eugene R. Schiff, Teresa L. Wright, et al.. (1998). Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis be-antigen (HBeAg) seroconversion. Gastroenterology. 114. A1235–A1235. 22 indexed citations

18.

Guðnason, Þórólfur, David L. Dunn, Nathaniel Brown, & Henry H. Balfour. (1991). Human herpes virus 6 infections in hospitalized renal transplant recipients. Clinical Transplantation. 5(5). 359–364. 5 indexed citations

19.

Brown, Nathaniel, et al.. (1987). B-cell lymphoma in severe combined immunodeficiency not associated with the Epstein–Barr virus. Cancer. 60(12). 2941–2947. 10 indexed citations

20.

Heston, Lee, M S Rabson, Nathaniel Brown, & George Miller. (1982). New Epstein–Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature. 295(5845). 160–163. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact